摘要
目的观察雷珠单抗治疗非缺血型视网膜分支静脉阻塞(branch retinal vein occlusion,BRVO)继发黄斑水肿(macular edema,ME)的疗效。方法选取于本院行玻璃体腔内注射雷珠单抗治疗的27例(27眼)BRVO继发ME患者作为实验组,20例(20眼)正常人作为对照组。对实验组患者,治疗前、治疗后1周及治疗后1、2、3、6个月,观察其裸眼视力(uncorrected visual acuity,UCVA)、最佳矫正视力(best corrected visual acuity,BCVA)、眼压(intraocular pressure,IOP)、中心凹视网膜厚度(central retinal thickness,CRT)、黄斑中心体积(central macular volume,CMV)及EN FACE图像情况;对正常对照组受试者,在入组当天、入组后1周及入组后1、2、3、6个月时,采用光学相干断层扫描仪进行CRT和CMV检查。结果实验组玻璃体腔注射次数为(3.26±0.59)次,治疗成功率为85.19%;治疗前后眼压相比,差异均无统计学意义(P>0.05);治疗后BCVA均较治疗前上升,差异均有统计学意义(P<0.001);治疗后CRT及CMV均较治疗前下降,差异均有统计学意义(P<0.01);与正常对照组相比,实验组治疗前后各时间段CRT及CMV比较,差异均有统计学意义(P<0.05),治疗后6个月CRT及CMV比较,差异无统计学意义(P>0.05);EN FACE显示经玻璃体腔内注射抗雷珠单抗治疗后黄斑厚度逐渐下降,视网膜水肿消退,囊腔样改变逐渐消失,光感受器椭圆体带层间结构也逐渐恢复。结论玻璃体腔内注射抗雷珠单抗对治疗非缺血型BRVO继发ME有显著的疗效,EN FACE是评估患者病情严重程度及治疗预后有效检查手段。
Objective To observe the efficacy of intravitreal injection of ranibizumabin the treatment of macular edemasecondary to non-ischemic branch retinal vein occlusion(BRVO).MethodsThe 27 patients(27 eyes)with macular edema secondary to non-ischemic BRVO,diagnosed by ophthalmology in Chongqing University Center Hospital from May 2018 to April 2019,were selected as the experimental group,and 20 cases(20 eyes)of normal people served as the control group.For the experimental group,before treatment,and at 1 week,1 month,2 months,3 months and 6 months after treatment,the uncorrected visual acuity,best corrected visual acuity,intraocular pressure,central retinal thickness,macular center volume and EN FACE imageswere observed.Study participantsin the normal control group were examined by optical coherence tomography for central retinal thickness and macular center volumeon the day of enrollment,1week,1month,2months,3months and 6monthsafter enrollment.ResultsThe mean age of patients in the experimental group was(67.37±8.63)years old and the number of intravitrealinjection was(3.26±0.59).The successful rate of treatment was 85.19%.There was no significant difference in intraocular pressure between pre-treatment and 1 week,1 month,2 months,3 months and 6 months posttreatment(P>0.05).At 1 week,1 month,2 months,3 months and 6 months aftertreatment,best corrected visual acuity were significantly higher than those before treatment(P<0.001).The levels of central retinal thickness and central macular volume at 1week,1 month,2 months,3 months and 6 months after treatment were significantly lower than those before treatment(P<0.01).Compared with the normal control group,the central retinal thicknessand central macular volume of the experimental group before and after treatment showed statistically significant differences in 1week,1month,2months and 3months(P<0.05).There was no statistically significant differenceincentral retinal thicknessand central macular volumeat 6monthsafter treatment(P>0.05).EN FACE showed that 1 week,1 month,2
作者
刘珏
陈再洪
LIU Jue;CHEN Zai-hong(Chongqing University Center Hospital, Chongqing Emergency Medical Center, Chongqing Fourth People’s Hospital, Ophthalmology,Chongqing400014,China)
出处
《海南医学院学报》
CAS
2020年第2期126-132,共7页
Journal of Hainan Medical University
基金
2017年重庆市卫生计生委医学科研项目(2017MSXM091)~~
